A
Anil Chandraker
Researcher at Brigham and Women's Hospital
Publications - 225
Citations - 11075
Anil Chandraker is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 51, co-authored 215 publications receiving 9892 citations. Previous affiliations of Anil Chandraker include Lahey Hospital & Medical Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection
H. Azuma,Anil Chandraker,Kari C. Nadeau,Wayne W. Hancock,Charles B. Carpenter,Nicholas L. Tilney,Mohamed H. Sayegh +6 more
TL;DR: The results indicate that T-cell recognition of alloantigen is a central event in initiating the process of chronic rejection, and that strategies targeted at blocking T- cell costimulation may prove to be a valuable clinical approach to preventing development of the process.
Journal ArticleDOI
CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis
John Reynolds,Frederick W.K. Tam,Anil Chandraker,Jennifer A. Smith,Ayman M. Karkar,Jane Cross,Peach Robert J,Mohamed H. Sayegh,Charles D. Pusey +8 more
TL;DR: It is concluded that CD28-B7 blockade reduced autoantibody production and cellular infiltration of glomeruli, and prevented target organ injury in EAG, suggesting a key role for B7.1.1 in costimulation of Th1-like autoimmune responses in the rat.
Journal ArticleDOI
Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients
S. Korom,I. De Meester,T.H.W Stadlbauer,Anil Chandraker,Meike Schaub,Mohamed H. Sayegh,A. Belyaev,A. Haemers,Simon Scharpé,Jerzy W. Kupiec-Weglinski +9 more
TL;DR: The model of targeting CD26/DPP IV may reveal essential interactions on the level of costimulatory alternate T cell activation pathways, allowing a more subtle approach for more selective immunosuppression in transplant recipients.
Journal ArticleDOI
The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.
B. T Lee,Vineeta Kumar,Timothy A Williams,Reza Abdi,Andrea J. Bernhardy,Christine Dyer,S Conte,Giulio Genovese,Michael D. Ross,David J. Friedman,Robert S. Gaston,Edgar L. Milford,Martin R. Pollak,Anil Chandraker +13 more
TL;DR: It is concluded that APOL1 genotypes do not increase risk of allograft loss after kidney transplantations, and carrying 2 APol1 risk alleles should not be an impediment to transplantation.
Journal ArticleDOI
Pharmacoepidemiology of Anemia in Kidney Transplant Recipients
Wolfgang C. Winkelmayer,Reshma Kewalramani,Mark Rutstein,Steven Gabardi,Tania Vonvisger,Anil Chandraker +5 more
TL;DR: It is concluded that PTA is prevalent and undertreated in KTR, and female gender and lower renal function were associated with lower HCT (both P < 0.001).